Join to View Full Profile
1600 SW Archer RoadGainesville, FL 32608
Phone+1 352-273-7766
Dr. Das is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Devika Das, MD, is an oncology specialist based in Gainesville, FL, with subspecialties in hematologic oncology and thoracic cancer. She completed her fellowship in hematology and medical oncology, and her residency in internal medicine at the University of Alabama Medical Center. Additionally, she holds a Master's in Healthcare Quality and Safety from UAB School of Health Professions. Dr. Das is currently an Associate Professor at the University of Florida and continues her role as an Assistant Professor at UAB Health System. She is also a Medical Director at Parexel. Her published works focus on various oncology topics, including immune checkpoint inhibitors, breast cancer treatment, and safety in oncology care delivery.
Education & Training
UAB School of Health Professions MSHQS, Healthcare Quality and Safety, 2018 - 2020
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015- University of Alabama Medical CenterResidency, Internal Medicine, 2009 - 2012
Grant Medical CollegeClass of 2007
Certifications & Licensure
FL State Medical License 2024 - 2027
AL State Medical License 2009 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Risk of Knowledge Gaps Among Nononcologists Caring for Patients With Cancer: The Example of Immune Checkpoint Inhibitors.Garrett Bourne, Devika Das, Joseph O Jacobson, Navid Sadeghi
JCO Oncology Practice. 2024-10-01 - 4 citationsTargeting EMT using low-dose Teniposide by downregulating ZEB2-driven activation of RNA polymerase I in breast cancer.Brandon J Metge, Heba Allah M Alsheikh, Sarah C Kammerud, Dongquan Chen, Devika Das
Cell Death & Disease. 2024-05-08 - Physician Disruptive Behavior Compromising Safe Care Delivery.Monika Kumar, Devika Das, Therese M Mulvey, Navid Sadeghi
JCO Oncology Practice. 2024-03-01
Press Mentions
What Does It Mean to Be HER2 Positive in Lung Cancer | Oncology Brothers: Practice-Changing Cancer DiscussionsApril 21st, 2025- More “Bang for the Buck?” Keys to Decision-Making in Perioperative Early-Stage NSCLCMay 5th, 2023
- Should You Be “Wary of Immunotherapy” in Certain Patients With NSCLC?April 28th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
